For high-risk patients with CAP and cSSTI
Fifth-generation cephalosporin with broad coverage
Simple dosing with a flexible infusion time
Proven clinical efficacy in patients with CAP and cSSTI
Safety profile consistent with other cephalosporins
ZINFORO® in the treatment of CAP and cSSTI
The Capital − A Wing 1802, 18th Floor, Plot No C-70, G Block, Bandra Kurla Complex, Bandra (East) Mumbai − 400 051, India
® Trademark Proprietor – Forest Laboratories, LLC Licensed User – Pfizer Limited, India
To view the summary of prescribing
information for ZINFORO®, please click here.
For the use only of Registered Medical Practitioners or a Hospital or a Laboratory. Full prescribing information available on request.
CAP, community-acquired pneumonia; cSSTI, complicated skin and soft tissue infection.
These pages are not intended for patients or for members of the general public. The web pages contain promotional content.
If you select 'No', you will be redirected to Pfizer.co.in
For more details on, Who is a Registered Medical Practitioner*, please visit
https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/acts_rules/2016DrugsandCosmeticsAct1940Rules1945.pdf , Page No. 39, Rule 2 part (ee), last accessed on 13th September 2019.
Address: The Capital, A Wing, 1802, 18th Floor, Plot No. C-70, 'G' Block, Bandra Kurla Complex, Bandra East, Mumbai - 400051.